DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Switzerland
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
LONN logo

Lonza Group AG Stock Price

SWX:LONN Community·CHF 37.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 49 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

LONN Share Price Performance

CHF 538.00
-18.60 (-3.34%)
​
CHF 677.61
Fair Value
CHF 538.00
-18.60 (-3.34%)
20.6% undervalued intrinsic discount
CHF 677.61
Fair Value
Price CHF 538.00
AnalystConsensusTarget CHF 677.61
Fri, 24 Jul 26
Fair ValueCHF 677.61
Share Pricen/a

LONN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CHF 677.61 20.6% undervalued intrinsic discount

Vacaville And Visp Facilities Will Secure Future Biologics Demand

0users have liked this narrative
0users have commented on this narrative
33users have followed this narrative
LONN logo
Lonza Group
20.6% undervalued intrinsic discount

Vacaville And Visp Facilities Will Secure Future Biologics Demand

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 24 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
LONN logo

LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside

Fair Value: CHF 677.61 20.6% undervalued intrinsic discount
33 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Solid track record with adequate balance sheet.

1 Risk
4 Rewards
View Full Analysis

Lonza Group AG Key Details

CHF 6.9b

Revenue

CHF 4.3b

Cost of Revenue

CHF 2.6b

Gross Profit

CHF 1.5b

Other Expenses

CHF 1.1b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
15.48
37.14%
15.73%
51.1%
View Full Analysis

About LONN

Founded
1897
Employees
20141
CEO
Wolfgang Wienand
WebsiteView website
www.lonza.com

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Recent LONN News & Updates

User avatar
Narrative Update • Jul 24

LONN: Bioprocessing Recovery And ADC Deals Will Support Future Upside

Lonza Group's updated analyst price target edges higher to CHF 678, supported by broader target increases across the Street toward CHF 640 to CHF 760 as analysts factor in revised assumptions on fair value, discount rate, revenue growth, profit margin and future P/E levels. Analyst Commentary Recent research on Lonza Group points to a mixed but generally constructive stance, with several price target adjustments clustering between CHF 590 and CHF 760.

Recent updates

No updates

Lonza Group AG Competitors

NOVN logo

Novartis

Symbol: SWX:NOVN
Market cap: CHF 212.2b
GALD logo

Galderma Group

Symbol: SWX:GALD
Market cap: CHF 36.2b
SDZ logo

Sandoz Group

Symbol: SWX:SDZ
Market cap: CHF 29.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide